Sidney Robertson, APRN
Psychiatric/Mental Health · Columbus, OHNPI 1376313155
Payments from drug & device makers
Across 224 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$689
- Vanda Pharmaceuticals Inc.$530
- AbbVie$461
- E.r. Squibb & Sons, L.L.C.$387
- Neurocrine Biosciences, Inc.$352
- Otsuka America Pharmaceutical, Inc.$344
- plus $851 from 9 others
What the payments were for
- Food & beverage$3,602100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $689 |
| Vanda Pharmaceuticals Inc. | 27 | $530 |
| AbbVie | 33 | $461 |
| E.r. Squibb & Sons, L.L.C. | 23 | $387 |
| Neurocrine Biosciences, Inc. | 17 | $352 |
| Otsuka America Pharmaceutical, Inc. | 25 | $344 |
| Alkermes, Inc. | 16 | $218 |
| Teva Pharmaceuticals USA, Inc. | 8 | $141 |
| Lundbeck LLC | 8 | $128 |
| Axsome Therapeutics, Inc. | 5 | $105 |
| Indivior Inc. | 4 | $92 |
| Tris Pharma Inc | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Johnson & Johnson | 2 | $38 |
| Soleno Therapeutics, Inc. | 1 | $21 |
How this compares
$3,614 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 11 | $1,069 |
| Quetiapine Fumarate | 25 | $442 |
| Sertraline Hcl | 27 | $417 |
| Divalproex Sodium | 12 | $263 |
| Buspirone Hcl | 13 | $218 |
| Risperidone | 15 | $208 |
| Olanzapine | 12 | $188 |
| Duloxetine Hcl | 12 | $174 |
| Hydroxyzine Hcl | 12 | $136 |
| Hydroxyzine Pamoate | 11 | $133 |
| Trazodone Hcl | 18 | $88 |
| Lamotrigine | 16 | $72 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Columbus
- Holly SchweitzerColumbus$78K
- David HuffmanColumbus$50K
- Tarsicio GacheruColumbus$18K
- Alicja MatusiakColumbus$11K
- Summer LawsonColumbus$11K
- Gregory BlankenshipColumbus$10K
- Jennifer WilsonColumbus$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.